BaracludeTreatment for Chronic Hepatitis B
Bristol-Myers Squibb Submits Applications in U.S. and Europe to Market Entecavir, an Investigational Antiviral Treatment For Chronic Hepatitis B Infection
PRINCETON, N.J., October 04, 2004 -- Bristol-Myers Squibb Company today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B. In the European Union, the Company also submitted a marketing authorization application for entecavir to the European Medicines Evaluation Agency.
Entecavir is an investigational oral antiviral discovered at Bristol-Myers Squibb that is designed to selectively inhibit the Hepatitis B virus, blocking all three steps in the replication process.
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
Posted: October 2004
- U.S. Food and Drug Administration Approves Baraclude (entecavir) as a Treatment for Chronic Hepatitis B Patients with Evidence of Decompensated Liver Disease - October 18, 2010
- Baraclude Bristol-Myers Squibb Company - Treatment for Chronic Hepatitis B - March 29, 2005
- Bristol-Myers Squibb Statement on FDA Advisory Committee Vote on Baraclude (entecavir), an Investigational Oral Antiviral Agent for Chronic Hepatitis B - March 11, 2005